Using a new controlled mixing process, highly transfection-competent polyplexes were formed and subsequently encapsulated within a lipid bilayer. The resulting ''pre-condensed stable plasmid lipid particles'' (pSPLPs) have small size (10473 nm) and low surface charge characteristics. The formulation process equally enabled lipid encapsulation of either poly-L-lysine or poly(ethyleneimine) (PEI) condensed DNA, and the endosomolytic benefits of PEI were demonstrated in in vitro gene expression studies. The clearance properties of pSPLP were compared to similar formulations with an uncondensed payload (SPLP) in A/J mice bearing subcutaneous Neuro-2a tumors. Plasma clearance of pSPLP (t 1/2 ¼ 6.6 h) was similar to SPLP (t 1/2 ¼ 7.1 h), allowing significant accumulation at distal tumor target sites. Gene expression profiles were evaluated in vivo using the Neuro-2a model, and PEI-pSPLP formulations demonstrated a sixfold increase in reporter gene expression in tumors compared to SPLP. No significant gene expression was observed in the liver, lung, or spleen when mice were treated with either SPLP or pSPLP, and both formulations were equally well tolerated. The results support the lipid encapsulation of polyplex plasmid DNA as a means of changing its pharmacologic properties and enabling systemic delivery. The inclusion of endosomolytic DNA-condensing agents such as PEI greatly improves the potency of SPLP.
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INTRODUCTION
The most common non-viral vectors for delivery of nucleic acids are the DNA-cationic lipid complexes (lipoplexes) [1] [2] [3] [4] and complexes formed by mixing nucleic acids with synthetic polycations (polyplexes). 5, 6 Fundamentally, both approaches rely on the spontaneous formation of electrostatic complexes between a cationic component and the negatively charged nucleic acid. However, these vectors exhibit certain disadvantages when administered systemically. Both systems are heterogeneous, metastable preparations, often aggregating and exhibiting variable transfection efficiencies. With a high positive surface charge, the systemic delivery of these systems often fails due to nonspecific interactions with blood components, activation of the complement system, 7 or uptake by non-target tissues such as the liver and the lung. 8 These factors limit the plasma circulation time [9] [10] [11] [12] and consequently the amount of therapeutic material that reaches the intended target cells. The shielding of polyplexes by covalent attachment of charge-neutral, hydrophilic polymers such as polyethylene glycol (PEG) has been reported to improve polyplex delivery to tumors following intravenous administration. [13] [14] [15] To address the limitations of currently available non-viral vector systems, we have developed stable plasmid lipid particles (SPLPs) for systemic administration. [16] [17] [18] [19] [20] SPLPs, a type of stable nucleic acid lipid particle, consist of a lipid bilayer encapsulating a single copy of plasmid DNA. SPLPs are monodisperse, with small size and low surface charge. The physical characteristics of SPLPs allow extended circulation lifetimes and the ability to bypass ''first pass'' organs, and accumulate at disseminated sites of disease. They are prepared quickly and reproducibly on scales ranging from milligrams to grams of encapsulated DNA. 20 A key lipid component of SPLP is the PEG-lipid, which provides the particle with a hydrophilic coating that both stabilizes the structure of the particle and shields the positive surface charge, thereby preventing rapid systemic clearance. The SPLP platform has proven to be robust, facilitating easy substitution of individual lipids and predictable manipulation of SPLP pharmacology. 19, 21, 22 In this study, we utilize the modular nature of the SPLP platform to incorporate additional functionality into the particle.
Poly(ethyleneimine) (PEI) has been widely used in transfection studies both in vitro and in vivo. 23 It has an advantage over other nucleic acid-condensing polymers, in that it has an intrinsic endosomolytic nature. This is conferred by the ''protonsponge'' effect, as described by Behr, 24 and reflects PEI's ability to buffer the endosomal compartment, reducing the rate of endosomal acidification. The model suggests that as protons are pumped into the endosome, PEI becomes increasingly protonated, and osmotic swelling of the compartment ensues, leading to its rupture and release of the polyplex into the cytoplasm. This is thought to aid the cytoplasmic delivery of payloads and to prevent their degradation in the lysosome. We hypothesized that if preformed polyplexes were encapsulated in a lipid bilayer analogous to SPLP, the characteristic small size, particle stability, and charge-shielding properties of the liposomal system could be conferred upon the polyplexes enabling their delivery to distal disease sites. Synergistically, the endosomolytic and nuclear delivery benefits of the PEI polymer would be brought to the SPLP platform.
Here, we show that PEI-plasmid DNA polyplexes can be encapsulated within a lipid bilayer to form pre-condensed SPLPs (shown schematically in Figure 1 ). Unlike regular polyplexes, pSPLPs exhibit disease site-targeting properties and accumulate at distal tumor sites after systemic administration. We describe the preparation of pSPLPs, their pharmacokinetics, and improved gene expression properties in a murine tumor model.
RESULTS

Formation of SPLP and pSPLP
To accomplish formation of pSPLP, a modified version of the spontaneous vesicle formation method 20 was applied. Before vesicle formation, plasmid DNA was complexed with PEI, creating a small, uniform polyplex preparation. This was achieved using a modification of the method of Jeffs et al 20 to mix 10 kDa branched PEI and plasmid DNA in continuous flow. Subsequently, the aqueous polyplex solution was mixed with an ethanolic solution of the lipids, resulting in instantaneous formation of pSPLP. An initial total lipid concentration of 10 mM was used in each case.
The physical characteristics of the resulting pSPLP and SPLP are shown in Table 1 . The process changes required for encapsulation of polyplex appeared to have no negative effect on particle formation. In fact, the initial encapsulation (calculated immediately after the particle formation step) was more efficient (99% for pSPLP versus 85% for SPLP). The pSPLP formulation process was straightforward, resulting in particles similar in size (104 nm) to SPLP (110 nm). Both are small enough to take advantage of the enhanced permeation and retention effect 25 and pass through the fenestrae that characterize the blood vessels of tumors and sites of inflammation and infection, 26 allowing passive tumor targeting. The amount of nucleic acid payload encapsulated in the final product was excellent in each case, 99% for pSPLP and 96% for SPLP. The pSPLP formulation consisted of a slightly more diverse population of particles, as evidenced by the polydispersity measurement (0.21, as opposed to 0.13 for SPLP). This suggests that pSPLPs are slightly more heterogeneous than their SPLP counterparts, a hypothesis that is corroborated by cryotransmission electron microscopy (cryo-TEM) results.
Cryo-TEM
The structures of pSPLP and SPLP were visualized by cryo-TEM ( Figure 2 ), a technique that has been used previously in the study of liposome morphology, including that of DNA-lipid complexes 27 and SPLP. 20, 28 As reported previously, 20 SPLPs prepared using spontaneous vesicle formation appear to have three distinct particle morphologies ( Figure 2b) ; unilamellar and bilamellar vesicles, both in the order of 70-100 nm in diameter, make up a large part of the sample. These are punctuated by a third, smaller, denser particle type, approximately 30-50 nm in diameter. The morphology of the pSPLP (Figure 2a) is very similar to that of SPLP (Figure 2b) . Both bilamellar vesicles, in the region of 70-100 nm diameter, and unilamellar vesicles are again observed. The third, smaller particle type is more prevalent in pSPLP, possibly accounting for this system's larger polydispersity value.
In vitro transfection demonstrates utility of endosomolytic polymers In order to determine the relative contribution of the endosomolytic activity of the polycation in the transfection process, pSPLPs were prepared using either poly(L-lysine) (PLL) or PEI as a precondensing agent. The formulations were used to transfect Neuro2a cells in the presence or absence of the endosomotropic agent chloroquine. It was hypothesized that in the absence of chloroquine, PEI-pSPLP would yield higher transfection levels than PLL-pSPLP, as PEI has the advantage of endogenous endosomolytic properties. When used in conjunction with chloroquine however, PLL-pSPLP gene delivery will benefit from the endosomolytic properties of this agent, and a marked increase in gene expression should be observed. PEI-pSPLP should not benefit from such a performance increase with chloroquine, as the structure of PEI already possesses these properties.
This appeared to be the case; PEI-pSPLP alone yielded significantly greater levels of gene expression than PLL-pSPLP when used to transfect Neuro-2a cells (82 pg luciferase/mg protein versus 12 pg/mg, Po0.05) ( Figure 3 ). When chloroquine was added, gene expression from PEI-pSPLP increased 2.2-fold to 184 pg/mg, whereas the potency of PLL-pSPLP increased 9.6-fold to 113 pg/mg. 
Pharmacokinetics-clearance and biodistribution
The circulation lifetime of pSPLP, and the ability to bypass ''firstpass'' organs and accumulate at distal tumor sites, was of obvious interest. To assess plasma clearance rates, pSPLP and SPLP were prepared containing the non-exchangeable lipid label, tritiated cholesteryl hexadecyl ether ( 3 H-CHE), and used to treat mice bearing subcutaneous Neuro-2a tumors via a single tail vein injection. The resulting clearance properties are described in Figure 4 . The initial phase of the elimination curve (from 0 to 8 h, representing the clearance of the majority of the dose) was used to determine half-life, using a first-order, non-compartmental model. Log values of the plasma concentrations were plotted against time to yield straight lines, the slopes of which were used to calculate half-life. Plasma half-life values were calculated as 6.6 and 7.1 h for the pSPLP and SPLP systems, respectively, demonstrating that lipid encapsulation of PEI polyplex confers a similar circulation lifetime to those reported previously for SPLP. 19, 22 The ability of pSPLP to bypass the first-pass organs and accumulate at distal tumor sites was also assessed, and accumulation in the liver, lung, spleen, heart, and tumor 24 h after administration is shown in Figure 5a . The biodistribution of pSPLP is similar to SPLP, with both particle types collecting to a greater extent in organs of the reticulo-endothelial system. pSPLP tends to accumulate slightly more in these organs (28% injected dose per gram of liver, 46% injected dose per gram of spleen) than SPLP (18 and 32%, respectively). Both formulations demonstrate low levels of accumulation in the lung, a further indication that the polyplexes of pSPLP are fully encapsulated. The extended circulation lifetime allowed for significant accumulation at the tumor site, with 7.5% of the injected dose of pSPLP, and 11% of SPLP accumulating per gram of tumor tissue. The differences between pSPLP and SPLP were significant (Po0.05) for all tissues apart from the liver.
Biodistribution of gene expression
The ultimate goal of this work is to enable the systemic delivery, and subsequent expression of polymer-condensed and -complexed DNA at a tumor target. The selectivity of gene expression at the tumor target, as compared to other tissues, is therefore of interest, and expression profiles for pSPLP and the SPLP control were assessed. A/J mice bearing Neuro-2a tumors received formulations containing 100 mg of DNA and 2 mg total lipid in a 200 mL volume, and reporter gene expression in the liver, spleen, lung, heart, and tumor was determined after 48 h (Figure 5b ). Both systems exhibit profound differentials in luciferase gene expression between tumors and non-target tissues (Po0.05). SPLP yielded luciferase concentrations of approximately 500 pg/ g in the tumor, at least 50-fold higher than other tissues, and 500-fold that observed in the liver. Similarly, pSPLP produced nearly 3,000 pg/g in the tumor, more than 300-fold that observed in non-target tissues and, in particular, 1,000-fold greater than the gene expression observed in the liver.
When comparing pSPLP to the SPLP control, the difference in gene expression levels in non-target tissues is not significant. However, the sixfold differential between pSPLP and SPLP in the tumor is significant (Po0.05). When considering the higher pSPLP gene expression (5,500 pg/g versus 1,700 pg/g for SPLP) in light of its less efficient accumulation (7.5% for pSPLP versus 11.0% for SPLP, Figure 5a ) it appears that, once delivered to the tumor, pSPLP is a much more potent transfection reagent than SPLP. A visual representation of luciferase activity in each tissue, normalized to the dose of vector DNA that deposited it, is shown in Figure 5c .
Gene expression-tumor transfection time course of pSPLP versus SPLP We also determined the extent of gene expression in the tumor over a 96-h time period. SPLP and pSPLP (each containing 100 mg DNA) were administered to tumor-bearing mice in a volume of 200 mL. The resulting gene expression is illustrated in Figure 6 , revealing a steady increase 48-72 h immediately after injection, followed by a decrease at a similar rate. pSPLPs transfect the tumor to a much greater extent than SPLP at the 24, 48, and 72 h time points (Po0.05), although after 96 h, the difference between the gene expression resulting from pSPLP or SPLP is not significant. It should be noted that the maximum level of SPLP gene expression occurs at 72 h, whereas for pSPLP it is 48 h. The maximum gene expression resulting from pSPLP is 3.2 times greater than that of SPLP. Similarly, the area under the curve for the SPLP system is 75.9 ng h/g of tumor, whereas for the pSPLP it is 255 ng h/g, a 3.4-fold increase.
Toxicity-intravenous administration of pSPLP is well tolerated Finally, it was of interest to determine the relative toxicity of pSPLP and SPLP, as these formulations are ultimately intended for use in vivo. Serum levels of the transaminases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), were determined 48 h after intravenous administration of pSPLP or SPLP in mice. ALT and AST are respectively regarded as reliable indicators of liver tissue damage and more general, systemic tissue damage. SPLPs have previously been shown to cause only limited increases in the levels of these proteins in the blood, 17, 22 and the increases seen in this experiment are again nominal ( Figure 7) . Being within the limits defined as ''normal'' by the Canadian Council on Animal Care, we concluded that, in addition to the gains made in transfection efficiency, pSPLPs were well tolerated. 
DISCUSSION
The goal of this work was to apply the charge-shielding and extended circulation properties of SPLP encapsulating plasmid DNA to a polyplex system. This required an adaptation of the SPLP formulation methodology. When preparing SPLP, encapsulation is enabled by inclusion of the cationic lipid 1,2-dioleyloxy-N,N-dimethyl-3-aminopropane (DODMA) which, due to its positive charge, is thought to promote the assembly of the nascent bilayer fragments around the negatively charged pDNA. 20 As pSPLP formation requires the encapsulation of a polycationic polyplex, the situation is effectively reversed. This necessitates the replacement of the cationic lipid (DODMA) with an anionic homolog, in this case POPG (1-palmitoyl-2-oleoyl-sn -glycero-3-phospho-rac-(1-glycerol)), thereby reversing the charge relationship between the lipid envelope and encapsulated payload. The lipid composition of SPLP and pSPLP is otherwise similar, consisting of cholesterol, DSPC (1,2-distearoyl-snglycero-3-phosphocholine), PEG-succinoyl distearoylglycerol, and the charged lipid (DODMA or POPG) in a 55:20:10:15 molar ratio.
It is important to note the fundamental differences in formulation process and resulting structure between pSPLP particles and previously described lipopolyplexes, such as lipid-protamine-DNA complexes. 29, 30 The pSPLP process consists of initially condensing and complexing the nucleic acid with a cationic polymer, followed by mixing with an ethanolic solution of lipids. This process results in the lipid bilayer forming around the polyplex, ultimately resulting in complete encapsulation. Conversely, while formulation of lipopolyplexes similarly begins with the complexation of the DNA, the resulting polyplex is subsequently mixed with pre-formed liposomes. In this case, the interaction between the polyplex and lipids results in chargemediated association or aggregation rather than encapsulation per se. The cryo-TEM data for pSPLP (Figure 2a) clearly show a population of spherical vesicles, as opposed to the more heterogeneous aggregates formed when preparing lipopolyplexes.
In fact, the pSPLPs were remarkably similar in size and polydispersity to SPLP, both being in the order of 100 nm. Both SPLP and pSPLP particles are comprised of three particle subtypes; larger unilamellar and bilamellar structures with sizes of 70-100 nm, and a third, smaller (30-50 nm) and denser subtype. These are more prevalent in the pSPLP sample, resulting in a larger polydispersity value. When observed previously in SPLP preparations, it was proposed that these vesicles were empty liposomes. 28 The images seen in the pSPLP sample are quite different from the heterogeneous mixtures of aggregates observed when examining lipid/DNA complexes 27, 31 or lipopolyplexes. 32 To investigate the significance of PEI's endosomolytic properties in this application, PEI-pSPLPs were compared to pSPLP prepared using PLL in an in vitro transfection assay. Similarly to PEI, PLL is a cationic polymer used as a DNA complexation and delivery agent. 33 However, it does not share PEI's ability to buffer the endosomal compartment and, consequently, it is less endosomolytic than PEI. Therefore, pSPLPs prepared with PLL are felt to be a good control for examining this aspect of PEI-pSPLP character.
The modest increase in potency exhibited by PEI-pSPLP suggests that it has less to gain from the presence of the chloroquine, an anticipated result given the inherent protonsponge properties of PEI. The PLL-pSPLP, however, exhibits a much larger gain in potency, as would be expected as chloroquine enhances endosomal release in a manner that PLL itself is not capable of. It should be noted that the PEI-pSPLP was still significantly more efficacious than the PLL-pSPLP (Po0.05), possibly owing to improved cellular trafficking of PEI polyplexes, as suggested by Godbey et al.
34
Consistent with other studies presented here, this experiment was performed with pSPLP containing C 18 PEG-lipids. C 18 and other stably incorporated PEG-lipids are designed to exchange out of SPLP only after many hours in the blood compartment, lending them the stability and long circulation lifetime required for tumor accumulation. However, when examined in vitro, these properties are known to inhibit transfection of cells. (Higher levels of gene expression could be obtained using less stably integrated C 14 PEG-lipids, as reported by Ambegia et al.
)
It should also be noted that, for the purpose of comparing transfection efficiencies, the assumption is made that both sets of particles, those containing PEI and those containing PLL, are taken up into cells equally well.
For in vivo applications, accumulation and ultimately the efficacy of these particles rely on their ability to perfuse blood vessels of the target tumor (the enhanced permeation and retention effect 25 ), an attribute that requires an extended circulation lifetime. Steric stabilization of polyplexes with covalently attached hydrophilic polymers, such as PEG or poly(N-(2-hydroxypropyl)-methacrylamide), has been reported to have a modest effect on circulation lifetime. 14, 35, 36 However, the improved plasma half-lives remain much less than 1 h. In Figure 4 , we demonstrate that lipid encapsulation of PEI polyplex confers a half-life of more than 6 h on pSPLP. Further, almost 40% of the injected dose is still present in the blood after 8 h, again similar to the SPLP control. This suggests that, unlike many polymer-condensed formulations, the longevity of pSPLP in the blood is not adversely affected by the incorporation of the condensing agent.
Characterization of the biodistribution of charge-shielded polyplexes typically reveals that the majority of the injected dose accumulates in the liver. [35] [36] [37] The liver is well known for its central role in removing foreign particles from the circulation, 38 and we have previously observed similar results upon injection of SPLP. 19, 28 However, reporter gene expression in the liver is typically low, possibly owing to the bulk of the accumulation being in liver phagocytes (Kuppfer cells), and correspondingly gene expression in this organ is still comparatively low. For pSPLP, as for SPLP and polyplexes, the organs of the reticuloendothelial system were found to contain a high concentration of the administered dose. Crucially, however, as shown in Figure 5a , the extended availability of the particles in the blood provides for a significant portion of the dose to accumulate at the tumor site.
The gene expression data obtained with pSPLP compare favorably to other attempts to adapt polyplex to systemic delivery. pSPLP produced more than 300-fold the gene expression observed in non-target tissues and, in particular, 1,000-fold greater than the gene expression observed in the liver. Most polyplex yield 10-to 100-fold tumor gene expression selectivity at best, although Kircheis et al 37 reported similar results to those described here. Using the blood protein transferrin, covalently attached to PEI, they achieved 100-to 500-fold selectivity for the tumor when using a similar Neuro-2a tumor model. Similar levels of reporter gene expression were observed as for pSPLP, with nanogram quantities reported in the tumor. Their approach takes advantage of passive targeting conferred by the charge-shielding properties of transferrin as well as active tumor targeting because of the interaction with the cell-surface transferrin receptor. As biodistribution alone is unable to account for the large degree of selectivity in pSPLP gene expression, other factors must be considered. The mitotic index of the target cell population, 39 perturbations in transcriptional efficiency, 40 and an altered phenotype of the target tumor cells may all contribute to the high degree of tumor-selective gene expression observed with pSPLP.
Examination of the time course of tumor gene expression provided further evidence of the efficacy of pSPLP versus SPLP. A steady increase 48-72 h immediately after injection was followed by a decrease at a similar rate in both formulations. This gene expression pattern is typical of systemically administered cytomegalovirus-controlled reporter genes, as reported by other researchers. 19, 28, 29, 37 The maximum gene expression resulting from pSPLP is 3.2 times greater than that of SPLP. Similarly, the area under the curve for pSPLP is 3.4-fold larger, further endorsing the benefits of delivering the nucleic acid payload pre-condensed with the endosomolytic polymer.
In addition to the gains made in transfection efficiency, pSPLPs were found to be well tolerated. Mice exhibited no adverse visual reactions following treatment, and analysis of serum for the transaminases AST and ALT gave no indication of toxicity ( Figure 7) . Increases in these proteins in the blood generally indicate liver and systemic tissue damage respectively, and neither was found to be elevated above normal limits.
Conclusion
In conclusion, we have demonstrated the feasibility of systemically delivering polymer-pre-condensed plasmid DNA to a distal tumor using pSPLP, and highlighted the advantages of incorporating endosome-modulating properties. In doing so, the efficacy of the first generation SPLP has been greatly improved. Importantly, the manufacture of SPLP by spontaneous vesicle formation has been previously shown to be a fully scalable process, using nucleic acid on a multi-gram scale, and employing components that are inexpensive and easily synthesized. The method continues to demonstrate its utility by allowing for the substitution of lipids, incorporation of polyplex payloads, and performing with a high degree of reproducibility.
MATERIALS AND METHODS
Materials. DSPC, POPG, and cholesterol were purchased from Avanti Polar Lipids (Alabaster, AL). DODMA 21 and PEG-succinoyl distearoylglycerol 19 were prepared as described previously. 3 H-labelled CHE was obtained from Perkin-Elmer (Boston, MA). The Picogreen Quantitation Kit was obtained from Molecular Probes (Eugene, OR). GPR grade solvents were purchased from VWR Scientific (Edmonton, AB, Canada). All other chemicals were purchased from Sigma-Aldrich (Oakville, ON, Canada). The pCMVluc plasmid, encoding the luciferase reporter gene under the control of the cytomegalovirus promoter, was manufactured as described previously. 18 Preparation of SPLP. SPLPs at a total lipid concentration of approximately 10 mM were prepared using the method of spontaneous vesicle formation by ethanol dilution, as described previously. 20 The lipid composition was DSPC:cholesterol:PEG-lipid:DODMA (20:50:10:20 molar ratio). Nucleic acid encapsulation and encapsulation efficiency were determined using a PicoGreen assay and comparing fluorescence in the presence and absence of Triton X-100, as described previously. 20 Particle size was determined by quasielastic light scattering using a Malvern Instruments Zetasizer 3000HSA (Malvern, UK). Intensity-weighted, Gaussian distribution analysis was used to determine mean vesicle diameters and population standard deviations. Polydispersity was reported using the ''Contin'' mode of the instrument's PCS software.
Preparation of pSPLP. pSPLPs with a lipid composition of DSPC:Cholesterol:PEG-lipid:POPG (20:50:10:20 molar ratio), at a total lipid concentration of approximately 10 mM, were similarly prepared using an adaptation of the spontaneous vesicle formation method. In brief, polyplexes were formulated by initially combining aqueous streams of plasmid DNA (900 mg/mL) with either 10 kDa branched PEI (N/P ratio of 10.5:1) or 42k PLL ( þ ve/Àve ratio of 3:1), using the apparatus described by Jeffs et al. 20 The resulting polyplexes were incubated at room temperature for 10 min. Polyplexes were then mixed with lipids in 90% ethanol using the same continuous flow mixing apparatus. The resulting pSPLPs were subsequently diluted with an equal volume of 300 mM NaCl, before concentration and dialysis with 20 volumes of N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid-buffered saline by tangential flow ultrafiltration. pSPLPs were finally filtered using 0.8/ 0.2 mm syringe filters and stored at 41C before use.
A variation of the PicoGreen assay, 20 incorporating 500 kDa dextran sulfate to dissociate unencapsulated polyplexes, was used to determine the percentage of nucleic acid encapsulation. This was performed both immediately after particle formation (to investigate the efficiency of the process), and on the final product. Encapsulation efficiency was calculated by comparing fluorescence in the presence and absence of Triton X-100 using a Varian Eclipse Spectrofluorometer (Varian, Palo Alto, CA). Particle size was determined as described.
In vitro transfection. Neuro-2a cells were cultured in minimum essential medium (Life Technologies, Burlington, ON, Canada) supplemented with 10% fetal bovine serum (Intergen, MA) at 371C with 5% CO 2 . Cells were dispensed into 24-well plates, with each well receiving 5 Â 10 4 cells and 1 mL of growth medium, and incubated overnight. Before dosing, dextran sulfate (300 mg/mL) was added to pSPLP (10 mg/mL DNA) and the suspension incubated at room temperature for 1 h, to disrupt unencapsulated polyplexes. This suspension was then diluted 1/10 with minimum essential medium, 1 mL added to each well, and incubated at 371C for 48 h. For cells receiving chloroquine treatment, the transfection media also contained chloroquine (40 mM). The cells were then washed twice with phosphatebuffered saline and lysed with 200 mL 250 mM sodium phosphate containing 0.1% Triton X-100. The luciferase activity for each well was determined using luciferase reagent (Promega, Madison, WI) and a standard luciferase protein (Roche, Mississauga, ON, Canada). The luminescence for each was measured using a Berthold MicroLumatPlus LB96V plate luminometer. The resulting luciferase activity was then normalized for the amount of protein using the Micro BCA assay kit (Pierce, Rockford, IL). For this experiment, n ¼ 3.
Blood clearance and biodistribution studies. Neuro-2a neuroblastoma cells were cultured and seeded in 7-week-old A/J mice (Harlan, Indianapolis, IN) as described previously.
19 SPLP or pSPLP containing 3 H-CHE (1.0 mCi/mg of total lipid) was prepared as described previously. Thirteen days after tumor seeding, 100 mg of SPLP or pSPLP DNA in a 200 mL injection volume was administered by lateral tail vein injection. At appropriate time points, 3 H-CHE was determined in whole blood by liquid scintillation counting, using Picofluor 15 and a Beckman LS6500 (Beckman Instruments, Fullerton, CA). For this experiment, n ¼ 6. Tissues were collected at the specified times and homogenized in lysing matrix tubes containing 500 mL of distilled water. Liver lysate (100 mL) and other lysates (200 mL) were assayed for radioactivity by liquid scintillation counting with Picofluor 40. The blood volume of each organ was determined by multiplying organ weight by a Blood Volume Correction Factor (distinct for each organ type). 41 In this way, a percentage of the measured counts that could be attributed to blood volume present was obtained, and subtracted from the total counts measured in the organ.
In vivo gene expression. Seven-week-old male A/J mice (Harlan, Indianapolis, IN) were inoculated subcutaneously in the hind flank with 1.5 Â 10 6 Neuro-2a cells 13 days before treatment. pSPLPs or SPLPs containing 100 mg DNA in a 200 mL injection volume or 200 mL phosphate-buffered saline were administered by lateral tail vein injection. Mice were killed 48 h after treatment. Liver, lungs, spleen, heart, and tumor were subject to analysis for luciferase gene expression as described previously. 19 For this experiment, n ¼ 4. For the gene expression time-course experiment, mice were killed at appropriate time points, and tumors were collected and assayed for luciferase gene expression (n ¼ 4).
Toxicity:AST/ALT. Seven-week-old male A/J mice (Harlan, Indianapolis, IN) were treated with pSPLP or SPLP (tail vein injection) containing 100 mg DNA in a 200 mL injection volume. Control mice were treated with 200 mL phosphate-buffered saline. Animals were killed 48 h after treatment. Serum was pooled for each group of mice and assayed for ALT and AST by the Central Laboratory for Veterinarians (Langley, BC, Canada). Error bars are not displayed as pooling of the serum samples was required to yield the necessary volume for AST/ALT analysis.
CryoTEM. Cryo-TEM of SPLP and pSPLP was performed at Uppsala University, Sweden, using a Zeiss EM 902A.
Statistical analysis of results. Significance of data was determined using either individual t-tests or Fisher's least significant difference test. Analysis of variance was performed followed by individual t-tests. A criterion of Po0.05 was used to define a significant result.
